Aurobindo's US Respiratory Filing Could Rival Teva's Qvar
As Indian Company Enters Fray For COVID-19 Vaccine
Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, Aurobindo hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges. Meanwhile, building on assets acquired from Profectus BioSciences, the firm has thrown its hat in the ring for a COVID-19 vaccine.
You may also be interested in...
Johnson & Johnson has added a manufacturing base in India’s Biological E as part of a global supply chain for its COVID-19 vaccine candidate. While Biological E will make 400-500 million dosages for the US firm, it has licensed for development another SARS-CoV-2 vaccine candidate from US-based Baylor College of Medicine.
As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products - they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.